Infinium Pharmachem
- Market cap
- ₹ 446 Cr.
- P/E
- 35.3x
- P/B
- 3.82x
- 52-week range
- 189.4 – 324.5
- ROE
- 11%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.19
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Infinium Pharmachem Limited is an India-based company. The Company is engaged in the development, manufacture, and export of a spectrum of the Iodine Derivatives that are used in pharmaceutical, chemical, biotech and allied industries across the globe. Its portfolio includes approximately 200+ Iodine Derivatives and seven Active Pharmaceutical Ingredients (APIs). It manufactures and supplies a range of Iodine-based APIs, but on an Order-to-Made basis only. It offers Bulk Actives, intermediates and services for custom synthesis. It also provides contract research and manufacturing services to pharmaceutical and biotech companies for their diverse requirements of Iodine-based APIs and intermediates to reduce their research time and project cost. It manufactures iodine derivatives for various industries, including pharmaceutical, chemical, nutraceutical, cosmetics, sanitation, agrochemical, electronics, nylon production, and other industries for their range of industrial applications.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Infinium Pharmachem against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)35.3 against a typical 34.3: pricier than most peers (1st = cheapest).116th of 220
- Sales growth+43.2% against a typical +15.6% from a year earlier.35th of 197
- Profit growth+60% against a typical +18.9% from a year earlier.43rd of 160
- Share price, 3 months+38.8% against a typical −0.5%.18th of 200
- Size₹ 445.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).103rd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated C by Acuite- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Acuite | ACUITE C | — | 20 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 20 Feb 2026 | Rating action | ACUITE C | — | Acuite | ₹ 6 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Nov 2026Upcoming | Financial Results | To consider and approve the half year financial results for the period ended September 30, 2026 |
| 22 Aug 2026 | Other business matters | To consider other business matters |
| 29 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 13 Mar 2026 | Other business matters | To consider other business matters |
| 13 Nov 2025 | Financial Results | To consider and approve the unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2025. |
| 21 Aug 2025 | Other business matters | To consider other business matters |
| 28 May 2025 | Financial Results/Other business matters | INFINIUM : 28-May-2025 : The Company has informed the Exchange that a Board meeting to be held on May 23, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 28, 2025, To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2022 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 79 | 61 | 74 | 83 | 73 | 84 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 74 | 94 |
| Operating Profit | 9 | 10 | 8 | 8 | 8 | 10 | 11 |
| OPM % | 11% | 17% | 11% | 10% | 11% | 12% | 11% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 8 | 8 | 7 | 6 | 5 | 8 | 10 |
| Tax % | 22% | 24% | 24% | 25% | 41% | 22% | 19% |
| Net Profit | 6 | 6 | 5 | 5 | 3 | 7 | 8 |
| EPS in Rs | 5.4 | 4.46 | 3.66 | 3.17 | 2.4 | 3.59 | 4.2 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 18%
- TTM
- 22%
- 10 Years
- —
- 5 Years
- 35%
- 3 Years
- 9%
- TTM
- 21%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 0%
- TTM
- —
- 10 Years
- —
- 5 Years
- 18%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Infinium Pharmachem | ₹ 310.00 | ₹ 446 Cr. | 35.3x | 3.8x | 11% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Sanjaykumar Viththalbhai Patel
- Executive Chairman of the Board, Managing Director
- Nilesh Dharamshi Bhai Patel
- Chief Financial Officer, Compliance Officer, Company Secretary
- Mitesh Lavjibhai Chikhaliya
- Executive Director
- Pravin Bhadabhai Madhani
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.